Liquidia reports Q3 net loss $9.1M; secures key legal wins for YUTREPIA launch

Liquidia Corp

2022-Q3 EPS reported -$0.58 revenue$10,575,000

Net loss $9.1M ($0.14/share) vs $7.3M loss in Q3 2021; revenue flat at $3.2M.
Cash $98.3M as of Sep 30, 2022 vs $57.5M at Dec 31, 2021.
PTAB ruled '793 patent claims unpatentable; court invalidated '066 patent claims, remaining not infringed; '901 non-infringed.
Launch of YUTREPIA (treprostinil) likely 12-14 months after PTAB denies rehearing on '793 appeal.
R&D spend $4.5M flat; G&A up 38% to $6.7M on commercial prep.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Liquidia Corp reported third quarter ended September 30, 2022 results: revenue $3.2 million.

Period: third quarter ended September 30, 2022
Revenue: $3.2 million
Result: reported results

Exact text from the filing

or dropping the device. Third Quarter 2022 Financial Results Cash totaled $98.3 million as of September 30, 2022, compared to $57.5 million as of December 31, 2021. Revenue was $3.2 million for the three months ended September 30, 2022, compared to $3.2 million for the three months ended September 30, 2021. Revenue related primarily to the Promotion Agreement.

View on SEC.gov

Browse all earnings releases →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-115699

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.